{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"155"},{"groupId":"OG002","value":"144"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"178"},{"groupId":"OG002","value":"172"}],"units":"Participants"}],"title":"Anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"148"},{"groupId":"OG002","value":"107"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"178"},{"groupId":"OG002","value":"171"}],"units":"Participants"}],"title":"Lymphocyte count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"62"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"177"},{"groupId":"OG002","value":"172"}],"units":"Participants"}],"title":"Neutrophil count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"178"},{"groupId":"OG002","value":"172"}],"units":"Participants"}],"title":"Platelet count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"151"},{"groupId":"OG002","value":"120"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"178"},{"groupId":"OG002","value":"172"}],"units":"Participants"}],"title":"Creatinine increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"27"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"161"}],"units":"Participants"}],"title":"Serum amylase increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"173"},{"groupId":"OG002","value":"159"}],"units":"Participants"}],"title":"Lipase increased"}],"denoms":[{"counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"182"},{"groupId":"OG002","value":"177"}],"units":"Participants"}],"description":"The number of participants with following laboratory abnormalities meeting any of the Grades 1 to 4 classified according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) toxicity grading version 4.03 were summarized: hematology (anemia, lymphocyte count decreased, neutrophil count decreased; and platelet count decreased) and chemistry laboratory tests (creatinine increased; serum amylase increased and lipase increased).","groups":[{"description":"Avelumab 10 milligram (mg)/kilogram (kg) given as a 1-hour intravenous (IV) infusion every 2 weeks (Q2W) in 4-week cycles.","id":"OG000","title":"Avelumab"},{"description":"Avelumab 10 mg/kg given as a 1-hour IV Q2W in 4-week cycles + pegylated liposomal doxorubicin (PLD) 40 mg/square meter given as a 1-hour IV infusion every 4 weeks (Q4W) in 4-week cycles.","id":"OG001","title":"Avelumab + PLD"},{"description":"PLD 40 mg/square meter given as a 1-hour IV infusion Q4W in 4-week cycles.","id":"OG002","title":"Pegylated Liposomal Doxorubicin (PLD)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"'Number of Participants Analyzed' is based on the safety analysis set, which included all participants who received at least 1 dose of study treatment. 'Number Analyzed' included the number of participants in the safety analysis set who can be evaluated for CTCAE criteria for each parameter in each treatment group.","reportingStatus":"POSTED","timeFrame":"From screening to the end of treatment/withdrawal visit, up to 2.7 years, based on cutoff date: 19 September 2018.","title":"Number of Participants With Laboratory Abnormalities","type":"SECONDARY","unitOfMeasure":"Participants"}